- Home
- VRAX vs XBIO Comparison
VRAX vs XBIO Comparison
Compare VRAX & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- XBIO
- Stock Information
- Founded
- VRAX 2013
- XBIO N/A
- Country
- VRAX United Kingdom
- XBIO United States
- Employees
- VRAX N/A
- XBIO N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- VRAX Health Care
- XBIO Health Care
- Exchange
- VRAX Nasdaq
- XBIO Nasdaq
- Market Cap
- VRAX 4.7M
- XBIO 4.2M
- IPO Year
- VRAX 2022
- XBIO N/A
- Fundamental
- Price
- VRAX $0.91
- XBIO $4.08
- Analyst Decision
- VRAX Strong Buy
- XBIO Hold
- Analyst Count
- VRAX 1
- XBIO 1
- Target Price
- VRAX $3.00
- XBIO N/A
- AVG Volume (30 Days)
- VRAX 46.8K
- XBIO 187.0K
- Earning Date
- VRAX 02-05-2025
- XBIO 08-12-2025
- Dividend Yield
- VRAX N/A
- XBIO N/A
- EPS Growth
- VRAX N/A
- XBIO N/A
- EPS
- VRAX N/A
- XBIO N/A
- Revenue
- VRAX $6,331.00
- XBIO $2,582,728.00
- Revenue This Year
- VRAX $217,274.83
- XBIO $14.23
- Revenue Next Year
- VRAX N/A
- XBIO $7.14
- P/E Ratio
- VRAX N/A
- XBIO N/A
- Revenue Growth
- VRAX N/A
- XBIO 5.63
- 52 Week Low
- VRAX $0.74
- XBIO $2.20
- 52 Week High
- VRAX $9.00
- XBIO $5.27
- Technical
- Relative Strength Index (RSI)
- VRAX 50.78
- XBIO 61.16
- Support Level
- VRAX $0.84
- XBIO $3.44
- Resistance Level
- VRAX $0.99
- XBIO $4.46
- Average True Range (ATR)
- VRAX 0.07
- XBIO 0.63
- MACD
- VRAX 0.02
- XBIO 0.05
- Stochastic Oscillator
- VRAX 60.20
- XBIO 54.79
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.